GlassScriptPhysician profile
Elaine Lima
NPI 1215688668
$3,813.41
in general payments reported to CMS, 2019-2025
21 companies · $647 in 2025
The $647 reported for 2025 was more than what 83% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $197 · 2023: $1,500 · 2024: $1,470 · 2025: $647.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,616.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,616.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,132.48 | 2023-2025 | Evenity, Repatha, Otezla |
| Abbvie INC. | $368.84 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $364.55 | 2024 | Airsupra, Farxiga |
| Novo Nordisk INC | $347.17 | 2022-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $309.96 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $259.71 | 2022-2025 | Arexvy, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $250.03 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $110.42 | 2023-2024 | Jynarque, Rexulti |
| Teva Pharmaceuticals USA, INC. | $102.85 | 2024-2025 | Austedo Xr, Austedo Xr |
| Sumitomo Pharma America, INC. | $100.81 | 2023-2025 | Gemtesa |
| Kowa Pharmaceuticals America, INC. | $78.88 | 2023-2024 | Livalo, Seglentis |
| Janssen Pharmaceuticals, INC | $71.63 | 2023-2024 | Xarelto |
| Pfizer INC. | $64.22 | 2023-2024 | |
| Idorsia Pharmaceuticals US INC | $61.14 | 2023 | Quviviq |
| Dexcom, INC. | $45.86 | 2022-2023 | Dexcom G6 Transmitter |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $45.05 | 2024-2025 | Cologuard Collection Kit |
| Corium, LLC | $23.08 | 2022 | |
| Esperion Therapeutics, INC. | $22.78 | 2023 | Nexletol |
| Sanofi Pasteur INC. | $22.33 | 2022 | |
| Insulet Corporation | $16.34 | 2025 | Omnipod |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.28 | 2024 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elaine Lima listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.